Henipavirus vaccine
US12201682B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 3, 2022 |
| Grant date | Jan 21, 2025 |
| Priority date | — |
| Expiry date | Nov 3, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18271
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Henipavirus, particularly Hendra virus and/or Nipah virus or a disorder related to such an infection. In particular, the present invention concerns a Hendra virus and/or Nipah virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.